Novartis Sees Reimbursement Advantage For PCSK9 Launch

 
• By Jessica Merrill

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

Buisness team and competition, Concept business vector illustration, Flat business cartoon, Overcome, Achieve success, Competitive, Performance. - Vector
Novartis sees better prospects for inclisiran than the other PCSK9 inhibitors

More from Drug Pricing

More from Scrip